CD44 and neoplasm: created a non-immunomodulating bsApt that targeted CD44 and EpCAM, two tumor cell surface markers that are overexpressed in ovarian cancer and are associated with malignant ascites, chemoresistance, decreased survival, and epithelial-to-mesenchymal transition (EMT).